PubRank

Ralf Kronenwett

Author PubWeight™ 48.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2009 7.21
2 A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011 2.79
3 A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012 1.83
4 Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008 1.74
5 Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 2011 1.44
6 Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 2012 1.37
7 Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013 1.34
8 Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 2002 1.33
9 Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 2002 1.32
10 Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med 2008 1.15
11 Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators. Blood 2004 1.12
12 Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 2007 1.04
13 HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013 1.04
14 Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003 0.95
15 Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res 2014 0.95
16 Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 2011 0.94
17 Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer 2012 0.91
18 Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004 0.91
19 The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Breast Cancer Res 2012 0.89
20 HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 2012 0.89
21 Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods 2005 0.88
22 A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006 0.88
23 Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biol Blood Marrow Transplant 2013 0.87
24 Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research. Virchows Arch 2012 0.85
25 The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant 2011 0.85
26 High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007 0.83
27 Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis. Angiogenesis 2006 0.83
28 Differential gene expression underlying the functional distinctions of primary human CD34+ hematopoietic stem and progenitor cells from peripheral blood and bone marrow. Ann N Y Acad Sci 2003 0.83
29 Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma. Ann Hematol 2006 0.82
30 Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 2004 0.82
31 Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol 2012 0.82
32 LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. Eur J Haematol 2005 0.78
33 Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector. Cancer Gene Ther 2003 0.78
34 Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera. Ann N Y Acad Sci 2005 0.78
35 Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 2015 0.78
36 Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. Clin Cancer Res 2005 0.77
37 Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. Exp Hematol 2002 0.76
38 Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2006 0.76
39 Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J Virol Methods 2002 0.76
40 Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol 2010 0.76
41 Molecular biology of hematopoietic stem cells. Vitam Horm 2003 0.76
42 Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer. Virchows Arch 2014 0.75
43 Molecular monitoring of minimal residual disease in patients with multiple myeloma. Hematology 2004 0.75
44 Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis. Leuk Res 2006 0.75
45 Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study. Hematol Oncol 2008 0.75